Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Zealand Pharma A/S (ZEAL : NSDQ)
 
 • Company Description   
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.

Number of Employees: 355

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.79 Daily Weekly Monthly
20 Day Moving Average: 6,582 shares
Shares Outstanding: 43.63 (millions)
Market Capitalization: $601.72 (millions)
Beta: 1.39
52 Week High: $34.30
52 Week Low: $9.93
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.30% 15.23%
12 Week -4.90% 4.56%
Year To Date -35.38% -21.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
SYDMARKEN 11
-
COPENHAGEN,G7 2860
DNK
ph: 45-8877-3600
fax: 45-8877-3898
investors@zealandpharma.com http://www.zealandpharma.com
 
 • General Corporate Information   
Officers
Emmanuel Dulac - President and Chief Executive Officer
Martin Nicklasson - Chairman of the Board of Directors
Matthew Dallas - Senior Vice President and Chief Financial Officer
Adam Sinding Steensberg - Executive Vice President
Jeffrey Berkowitz - Board member

Peer Information
Zealand Pharma A/S (CORR.)
Zealand Pharma A/S (RSPI)
Zealand Pharma A/S (CGXP)
Zealand Pharma A/S (BGEN)
Zealand Pharma A/S (GTBP)
Zealand Pharma A/S (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98920Y304
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 43.63
Most Recent Split Date: (:1)
Beta: 1.39
Market Capitalization: $601.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.53 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.62
Price/Cash Flow: -
Price / Sales: 14.64
EPS Growth
vs. Year Ago Period: 32.98%
vs. Previous Quarter: 37.00%
Sales Growth
vs. Year Ago Period: -70.66%
vs. Previous Quarter: -72.62%
ROE
03/31/22 - -89.90
12/31/21 - -78.06
09/30/21 - -82.62
ROA
03/31/22 - -50.80
12/31/21 - -51.58
09/30/21 - -60.10
Current Ratio
03/31/22 - 4.79
12/31/21 - 5.15
09/30/21 - 4.23
Quick Ratio
03/31/22 - -
12/31/21 - 4.80
09/30/21 - 3.85
Operating Margin
03/31/22 - -364.89
12/31/21 - -347.66
09/30/21 - -371.32
Net Margin
03/31/22 - -380.22
12/31/21 - -347.66
09/30/21 - -371.32
Pre-Tax Margin
03/31/22 - -364.34
12/31/21 - -351.01
09/30/21 - -365.12
Book Value
03/31/22 - 2.45
12/31/21 - 3.38
09/30/21 - 4.32
Inventory Turnover
03/31/22 - 1.00
12/31/21 - 0.98
09/30/21 - 1.17
Debt-to-Equity
03/31/22 - 0.93
12/31/21 - 0.70
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 48.26
12/31/21 - 41.12
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©